Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, RNAi, RIP, Luciferase reporter assay, in vitro knockdown etc. |
| Sample | bladder cancer tissues, cell lines (RT4, RT112, DSH1, 253J, TCCSUP etc.) |
| Expression Pattern | up-regulated |
| Function Description | Here we found that H19 levels are remarkably increased in bladder cancer tissues, and upregulated H19 promotes bladder cancer cell migration in vitro and in vivo. H19 is associated with enhancer of EZH2, and that this association results in Wnt/B-Catenin activation and subsequent downregulation of E-cadherin. A significant negative correlation is also observed between H19 levels and E-cad levels in vivo. upregulated H19 enhances bladder cancer metastasis by associating with EZH2 and inhibiting E-cad expression. |
| Pubmed ID | 23354591 |
| Year | 2013 |
| Title | Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |